5 terminated, 3 completed, 1 withdrawn. 9 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Terminated 5, Completed 3, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
Follow Hemoglobin SC Disease: new trials by email Literature Review of Hemoglobin SC Disease trials Research Report on Hemoglobin SC Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetics of Oral Hydroxyurea Solution Oral Hydroxyurea (100 mg/mL) Solution - Sickle Cell Disease, Sickle-Cell; Hemoglobin Disease, Thalassemia | Phase 1 / Phase 2 | Completed | Nova Laboratories Limited | 33 | 2019-01-03 | 2024-10-28 |
| Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC) crizanlizumab - Sickle Cell Disease (SCD) | Phase 2 | Completed | Novartis Pharmaceuticals | 57 | 2017-12-19 | 2024-10-09 |
| Treatment of Adult Patients With Hemoglobin SC Disease (SCYTHE) Hydroxyurea - Hemoglobin SC Disease | Phase 2 | Terminated | Baylor College of Medicine | 1 | 2015-10-12 | 2020-01-27 |
| Treatment of Hemoglobin SC Disease With Hydroxyurea hydroxyurea - Hemoglobin SC Disease | Phase 2 | Terminated | Baylor College of Medicine | 32 | 2014-12-01 | 2020-09-09 |
| Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis MP4CO, Sodium chloride solution - Anemia, Sickle Cell, Sickle Cell Anemia | Phase 2 | Withdrawn | Sangart | 2013-10-01 | 2013-10-28 | |
| Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease Hydroxyurea, Magnesium Pidolate, Placebo Pills and Placebo Liquid - Hemoglobin SC Disease | Phase 2 | Terminated | St. Jude Children's Research Hospital | 44 | 2007-01-01 | 2013-01-18 |
| Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies Busulfex, Fludarabine, Alemtuzumab - Hemoglobinopathies, Sickle Cell Disease | Phase 2 | Completed | Dana-Farber Cancer Institute | 2 | 2004-03-01 | 2013-07-30 |
| Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia Busulfan, Fludarabine, FK506 - Hemoglobinopathies, Anemia, Sickle Cell | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 2 | 2001-09-01 | 2013-05-01 |
| Oral Magnesium Pidolate, Hemoglobin SC Disease, MG Pidolate Mg Pidolate, Placebo - HEMOGLOBIN SC DISEASE | Phase 2 | Terminated | Baylor College of Medicine | 12 | 2001-01-01 | 2012-11-19 |
Anemia, Sickle Cell (6) · Hemoglobinopathies (3) · Thalassemia (3) · Vaso-Occlusive Crises (3) · Acute Chest Syndrome (1) · Graft vs Host Disease (1) · beta-Thalassemia (1)
Anemia (9) · Anemia, Hemolytic (9) · Anemia, Hemolytic, Congenital (9) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (9) · Genetic Diseases, Inborn (9) · Hematologic Diseases (9) · Hemic and Lymphatic Diseases (9) · Hemoglobinopathies (6) · Anemia, Sickle Cell (3) · Immune System Diseases (1) · Lung Diseases (1) · Respiration Disorders (1) · Respiratory Tract Diseases (1)
Hydroxyurea (4) · Busulfan (2) · Pyrrolidonecarboxylic Acid (2) · fludarabine (2) · Alemtuzumab (1) · PEGylated carboxyhemoglobin bovine (1) · Prednisone (1) · Saline Solution (1) · Sodium Chloride (1) · Solutions (1) · Tacrolimus (1) · crizanlizumab (1) · fludarabine phosphate (1)
Baylor College of Medicine (3) · Dana-Farber Cancer Institute (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Nova Laboratories Limited (1) · Novartis Pharmaceuticals (1) · Sangart (1) · St. Jude Children's Research Hospital (1)
United States (7) · United Kingdom (2) · Bahrain (1) · Belgium (1) · Brazil (1) · France (1) · Jamaica (1) · Lebanon (1) · Netherlands (1) · Qatar (1) · Turkey (Türkiye) (1)
Catherine J. Wu, MD (2) · Vivien Sheehan, MD (2) · Angela E Rankine- Mullings, MD (1) · Brigitta Mueller, MD (1) · Swee Lay Thein, MD (1) · Tania Small, MD (1) · Winfred C. Wang, MD (1)
PMID 14550808, PMID 18550258, PMID 21275961, PMID 36355805, PMID 36529836, PMID 39497751
2017 (1), U54HL070587 (1)